Gleevec (Imatinib 400mg) Global Pricing Disparity Workbench

30-Tablet Monthly Regimen: US Brand List ($9,850) vs Direct Cash Generic ($47) vs India Retail ($65)
● Model Active
US Brand List vs India Ratio
151.5x
US List $9,850/mo vs India $65/mo ($15,053% premium)
US Annual Brand Exposure
$118,200
Includes $46,200/yr intermediated PBM rebates
Direct Cash Generic Alternative
$564 / yr
Cost Plus / Generic Cash ($47/mo for 30 tabs)
Indian National Generic Cost
$780 / yr
Supreme Court Sec 3(d) Patent Ruling outcome
US Supply-Chain Margin Decomposition
Manufacturer Net Realization: $4,150
PBM Rebates & Formulary Fees: $3,850
Wholesaler / Distributor Markup: $650
Pharmacy Margin & Dispensing Fee: $1,200
Supply-Chain Margin Verdict: Out of the $9,850 monthly US list price, $3,850 (39.1%) is absorbed by PBM gross rebates, while the net manufacturer revenue is $4,150 (42.1%).
Interactive Waterfall Breakdown (30x 400mg Tablets) Total List: $9,850
Global Price & Policy Comparison (Imatinib 400mg)
Jurisdiction / Channel Pack Price Pricing Framework Status
Chronic Myelogenous Leukemia (CML) Patient Cost Simulator US HDHP Plan
Insurance Coinsurance Rate: 20%
Annual Out-of-Pocket Max / Deductible: $9,100
Treatment Timeline US Brand (Insured) US Generic Cash India Generic
Clinical Reality: CML patients require continuous lifelong daily imatinib therapy. In the US, patients quickly hit catastrophic out-of-pocket maximums every single January, whereas Indian or direct generic cash buyers pay less than 1/10th of the annual deductible.
Gleevec® (imatinib mesylate) 400mg pricing data calibrated to US Red Book AWP/WAC benchmarks, Mark Cuban Cost Plus Drugs, India NPPA retail caps (Novartis v. Union of India, 2013), and UK NHS BNF reference datasets.
Super generates helpful tools and automates fact-checking across the internet proactively. If you enjoyed this tool, build your own with Super and share it with a friend.